Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
China has always been believed to be the land of promise for multinational pharmaceutical companies. However, up until recently many organisations have struggled to see a return on their investments. That may all be set to change though.
The country’s recent 2020 healthcare reforms aim to rapidly increase the pace of new drug approvals and fast track innovative treatments, opening up a whole new world of opportunities for the pharmaceutical industry.
Register now for our next live webinar in which emerging markets experts Marc Yates and Helen Ansell will explore China’s evolving healthcare environment, highlight the key changes affecting pharma and show you how to  build the market understanding required to launch a brand effectively in this exciting region.
When: Tuesday 16th April 2019Â
Time: 10:00 EST/ 15:00 GMT / 16:00 CEST
Register now to secure your place »
China’s key growth factors:
Fast track approvals: So far, over 180 foreign pharma products have been granted priority review and will likely hit the market within the next few years.
From an ability to pay to willingness to pay: By 2022 more than half of the urban population will be defined as upper middle class and as incomes rise so does willingness to pay for quality healthcare.
Shifting disease patterns:Â Diseases of affluence are also on the rise and the benefits of urban life have resulted in an aging population and an explosion in age-related conditions.
What are the key takeaways in this webinar?Â
1. China 101Â
An overview of the healthcare environment in China
2. What’s changed?
The key opportunities under China’s 2020 healthcare reform
3. Where to play? How to win?
Design an effective marketing strategy with insights that prepare you for optimal success.
4. Gain answers to your key questions
Start the conversation by submitting your questions in advance when you register.
Register now to secure your place »
If you are unable to attend but would like to view the recording, register now and we will send you a unique link to download it as soon as it is ready.
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs, which includes links to...
APAC Director Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their real value to patients, healthcare and society.Watch the video:Â https://bit.ly/2OcOWNu
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Many of us are familiar with billiard games, where two players compete to be the first to pocket all the balls on the table in a particular order. We recently...
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Considerations when developing an appropriate pricing strategy in self-pay markets
Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...
Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...
Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...
Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year